Stack and protocol research questions — what combinations is the community studying

Kicking off this discussion thread for ongoing community input on peptide combination research questions. Stack design is one of the most-discussed practices in the peptide space and one of the least systematically studied — published controlled research on combinations is much thinner than on individual compounds. Community-level experience reports on combinations therefore add real value to a thinner literature base. Reply with your own questions or respond to anyone else's.

Specific questions or experiences worth sharing.

Recovery stack experiences (BPC-157 + TB-500 + GHK-Cu + ipamorelin or variations). If a research protocol used a multi-compound recovery combination, what specific compounds were in the stack, what were the dosing patterns and frequencies for each, and what were the observed outcomes? What injury type or recovery research context was being studied? How did the multi-compound protocol compare to a simpler 1-2 compound protocol if you have run both? The recovery stack thread covers the foundational protocol; community-level variations and outcomes add to that base.

GH peptide combination experiences. CJC-1295 + ipamorelin is the foundational GH stack. Variations include CJC-with-DAC plus an additional ghrelin mimetic, tesamorelin combinations, and protocols that add MK-677 to injectable secretagogues. If a protocol used any of these variations, what was the rationale and what was observed? Comparing multi-compound GH protocols to single-compound protocols (Tesamorelin alone, MK-677 alone) is one of the more interesting research questions in this category.

GLP-1 plus GH stack experiences. The body recomposition combination of GLP-1 peptide plus GH peptide is being investigated more in community settings than in published clinical research. If a protocol combined them, what was the rationale, what dosing patterns were used, and what were the body composition outcomes? Specific data (DEXA results, BIA results, photographic documentation) is more useful than general claims.

Cycling protocol experiences. The question of when to take breaks from peptide protocols and how long the breaks should be is debated and the published research does not give a clean answer. If a research protocol used cycling, what was the on/off schedule and what was the rationale? If a protocol ran continuously, how long did it run and were any tachyphylaxis or downregulation effects observed?

Adverse interaction experiences. If a stack produced unexpected effects that did not appear with the individual compounds — increased side effects, unexpected interactions, effects on blood markers that single compounds did not produce — please report. The published research does not adequately characterize multi-compound interactions and community-level observation is the primary data source.

Pre-mixed product experiences (for the cautionary record). If a research protocol used pre-mixed combination products from any vendor, what did you observe regarding ratio variability, concentration variability, or apparent quality differences from buying components separately? The Red Flags thread covers the case against pre-mixed products in detail; experience reports add to the empirical case.

A note on framing.
Stack design is one of the areas where the gap between "research framing" and "consumer protocol advice" is psychologically narrow. Please keep responses research-framed — describe what was done in research contexts, what was observed, what protocols were studied. Avoid prescriptive language. The platform's posture is research community and the long-term durability of this content depends on that discipline being maintained even in the most experimental subcategory.

A specific note on multi-compound protocols: be conservative in attributing observed effects to specific components. A 4-compound protocol that produced an outcome cannot reliably attribute the outcome to any one compound — only the combination is what was actually studied. Reports that say "I ran X stack and observed Y" are useful; reports that say "compound A is what caused the observed effect" cannot be supported by the research design unless A was tested in isolation in the same subject.

If you have questions but do not want to post them publicly, DMs are open. The thread is the right place for shareable Q&A but private messages work for protocol-specific or vendor-specific questions, particularly for novel combinations being investigated.